Guided Therapeutics (GTHP) Research & Development (2016 - 2025)
Historic Research & Development for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to $136000.0.
- Guided Therapeutics' Research & Development rose 2252.25% to $136000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $483000.0, marking a year-over-year increase of 211.42%. This contributed to the annual value of $526000.0 for FY2024, which is 13070.18% up from last year.
- As of Q3 2025, Guided Therapeutics' Research & Development stood at $136000.0, which was up 2252.25% from $133000.0 recorded in Q2 2025.
- In the past 5 years, Guided Therapeutics' Research & Development ranged from a high of $222000.0 in Q2 2024 and a low of $7000.0 during Q1 2023
- Over the past 5 years, Guided Therapeutics' median Research & Development value was $54000.0 (recorded in 2024), while the average stood at $65473.7.
- Over the last 5 years, Guided Therapeutics' Research & Development had its largest YoY gain of 76250.0% in 2023, and its largest YoY loss of 6666.67% in 2023.
- Guided Therapeutics' Research & Development (Quarter) stood at $17000.0 in 2021, then soared by 129.41% to $39000.0 in 2022, then surged by 120.51% to $86000.0 in 2023, then skyrocketed by 62.79% to $140000.0 in 2024, then decreased by 2.86% to $136000.0 in 2025.
- Its Research & Development was $136000.0 in Q3 2025, compared to $133000.0 in Q2 2025 and $74000.0 in Q1 2025.